Title:
TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
Document Type and Number:
WIPO Patent Application WO/2016/127924
Kind Code:
A1
Abstract:
The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.
More Like This:
Inventors:
WANG XIAOJUN (CN)
YANG XINYE (CN)
PAN SHENGQIANG (CN)
GUO RUI (CN)
WU JUNWEN (CN)
ZHANG YINGJUN (CN)
CHENG CHANGCHUNG (CN)
YANG XINYE (CN)
PAN SHENGQIANG (CN)
GUO RUI (CN)
WU JUNWEN (CN)
ZHANG YINGJUN (CN)
CHENG CHANGCHUNG (CN)
Application Number:
PCT/CN2016/073617
Publication Date:
August 18, 2016
Filing Date:
February 05, 2016
Export Citation:
Assignee:
SUNSHINE LAKE PHARMA CO LTD (CN)
International Classes:
C07D413/12; A61K31/42; A61K31/4353; A61K31/4985; A61K31/519; C07D261/08; C07D411/12; C07D471/04; C07D491/044; C07D497/04; C07D498/14
Domestic Patent References:
| WO2004026030A2 | 2004-04-01 | |||
| WO2000037077A1 | 2000-06-29 | |||
| WO2003015771A1 | 2003-02-27 | |||
| WO2004048349A1 | 2004-06-10 | |||
| WO2007076260A2 | 2007-07-05 | |||
| WO2007092751A2 | 2007-08-16 | |||
| WO2007140174A2 | 2007-12-06 | |||
| WO2007140183A1 | 2007-12-06 | |||
| WO2008051942A2 | 2008-05-02 | |||
| WO2008157270A1 | 2008-12-24 | |||
| WO2009005998A1 | 2009-01-08 | |||
| WO2009012125A1 | 2009-01-22 | |||
| WO2009149795A2 | 2009-12-17 | |||
| WO2008025539A1 | 2008-03-06 | |||
| WO2008025540A1 | 2008-03-06 | |||
| WO2012087520A1 | 2012-06-28 | |||
| WO2012087521A1 | 2012-06-28 | |||
| WO2012087519A1 | 2012-06-28 | |||
| WO2013007387A1 | 2013-01-17 | |||
| WO2015036442A1 | 2015-03-19 | |||
| WO2011020615A1 | 2011-02-24 | |||
| WO2011103202A2 | 2011-08-25 | |||
| WO2010011375A2 | 2010-01-28 | |||
| WO2009012125A1 | 2009-01-22 |
Foreign References:
| EP1182200A1 | 2002-02-27 |
Other References:
SEOL ET AL., MOL.ENDOCRINOL, vol. 9, 1995, pages 72 - 85
FORMAN, CELL, vol. 81, 1995, pages 687 - 693
MAKISHIMA ET AL., SCIENCE, vol. 284, 1999, pages 1365 - 1368
WANG ET AL., MOI.CELL., vol. 3, 1999, pages 543 - 553
URIZAR ET AL., J.BIOL.CHEM., vol. 275, 2000, pages 39313 - 393170
CRAWLEY, EXPERT OPINION THER. PATENTS, vol. 20, 2010, pages 1047 - 1057
FRANK G. SCHAAP ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, 2005, pages 5383 - 5402
R.C.BUIJSMAN ET AL., CURR. MED. CHEM., vol. 12, 2005, pages 1017 - 1075
M.L.CRAWLEY ET AL., EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 20, no. 8, 2010, pages 1047 - 1057
ELIEL, E.WILEN, S.: "Periodic Table, CAS version and chemical manuals", 1994, JOHN WILEY&SONS, INC.
"Organic Chemistry", 1999, THOMAS SORRELL, UNIVERSITY SCIENCE BOOKS
"March's Advanced Organic Chemistry", 2007, JOHN WILEY & SONS
"McGraw-Hill Dictionary of Chemical Terms", 1984, MCGRAW-HILL BOOK COMPANY
BERGE ET AL.: "pharmaceutically acceptable salts", J. PHARMACOL SCI, vol. 66, 1977, pages 1 - 19
L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514
T. HIGUCHIV. STELLA: "Bioreversible Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
J. RAUTIO ET AL.: "Prodrugs: Design and Clinical Applications", NATURE REVIEW DRUG DISCOVERY, vol. 7, 2008, pages 255 - 270, XP055227338, doi:10.1038/nrd2468
S. J. HECKER ET AL.: "Prodrugs of Phosphates and Phosphonates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, 2008, pages 2328 - 2345, XP008148502, doi:10.1021/jm701260b
T W. GREENE: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY&SONS
P. J. KOCIENSKI: "Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"Encyclopedia of Pharmaceutical Technology", 1988, W.B. SAUNDERS PUBLISHING COMPANY
BIOORG MED CHEM LETT., vol. 25, no. 2, 15 January 2015 (2015-01-15), pages 280 - 4
ORGANIC AND BIOMOLECULAR CHEMISTRY, vol. 16, no. 1, 2003, pages 2865 - 2876
BIOORG. MED. CHEM. LETT., vol. 25, no. 2, 2015, pages 280 - 284
See also references of EP 3256468A4
FORMAN, CELL, vol. 81, 1995, pages 687 - 693
MAKISHIMA ET AL., SCIENCE, vol. 284, 1999, pages 1365 - 1368
WANG ET AL., MOI.CELL., vol. 3, 1999, pages 543 - 553
URIZAR ET AL., J.BIOL.CHEM., vol. 275, 2000, pages 39313 - 393170
CRAWLEY, EXPERT OPINION THER. PATENTS, vol. 20, 2010, pages 1047 - 1057
FRANK G. SCHAAP ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, 2005, pages 5383 - 5402
R.C.BUIJSMAN ET AL., CURR. MED. CHEM., vol. 12, 2005, pages 1017 - 1075
M.L.CRAWLEY ET AL., EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 20, no. 8, 2010, pages 1047 - 1057
ELIEL, E.WILEN, S.: "Periodic Table, CAS version and chemical manuals", 1994, JOHN WILEY&SONS, INC.
"Organic Chemistry", 1999, THOMAS SORRELL, UNIVERSITY SCIENCE BOOKS
"March's Advanced Organic Chemistry", 2007, JOHN WILEY & SONS
"McGraw-Hill Dictionary of Chemical Terms", 1984, MCGRAW-HILL BOOK COMPANY
BERGE ET AL.: "pharmaceutically acceptable salts", J. PHARMACOL SCI, vol. 66, 1977, pages 1 - 19
L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514
T. HIGUCHIV. STELLA: "Bioreversible Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
J. RAUTIO ET AL.: "Prodrugs: Design and Clinical Applications", NATURE REVIEW DRUG DISCOVERY, vol. 7, 2008, pages 255 - 270, XP055227338, doi:10.1038/nrd2468
S. J. HECKER ET AL.: "Prodrugs of Phosphates and Phosphonates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, 2008, pages 2328 - 2345, XP008148502, doi:10.1021/jm701260b
T W. GREENE: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY&SONS
P. J. KOCIENSKI: "Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"Encyclopedia of Pharmaceutical Technology", 1988, W.B. SAUNDERS PUBLISHING COMPANY
BIOORG MED CHEM LETT., vol. 25, no. 2, 15 January 2015 (2015-01-15), pages 280 - 4
ORGANIC AND BIOMOLECULAR CHEMISTRY, vol. 16, no. 1, 2003, pages 2865 - 2876
BIOORG. MED. CHEM. LETT., vol. 25, no. 2, 2015, pages 280 - 284
See also references of EP 3256468A4
Attorney, Agent or Firm:
TSINGYIHUA INTELLECTUAL PROPERTY LLC (Trade Building Zhaolanyuan, Tsinghua University, Qinghuayuan, Haidian District, Beijing 4, CN)
Download PDF:
Previous Patent: MULTI-REGION WORK CONTROL SYSTEM AND CONTROL METHOD THEREFOR
Next Patent: DRUG COMBINATION OF FLAVONOID COMPOUND AND USE OF SAME
Next Patent: DRUG COMBINATION OF FLAVONOID COMPOUND AND USE OF SAME